[1] Aletaha, D., and J.S. Smolen. 2018. Diagnosis and Management of Rheumatoid Arthritis: A Review. Jama 320(13): 1360-1372.
[2] Sparks, J.A. 2019. Rheumatoid Arthritis. Ann Intern Med 170(1): Itc1-itc16.
[3] Firestein, G.S., and I.B. Mcinnes. 2017. Immunopathogenesis of Rheumatoid Arthritis. Immunity 46(2): 183-196.
[4] Rana, A.K., Y. Li, Q. Dang, and F. Yang. 2018. Monocytes in rheumatoid arthritis: Circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis. Int Immunopharmacol 65:348-359.
[5] Bartok, B., and G.S. Firestein. 2010. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233(1): 233-255.
[6] Ospelt, C., and S. Gay. 2008. The role of resident synovial cells in destructive arthritis. Best Pract Res Clin Rheumatol 22(2): 239-252.
[7] Ospelt, C. 2017. Synovial fibroblasts in 2017. RMD Open 3(2): e000471.
[8] Del Rey, M.J., E. Izquierdo, A. Usategui, E. Gonzalo, F.J. Blanco, F. Acquadro, and J.L. Pablos. 2010. The transcriptional response of normal and rheumatoid arthritis synovial fibroblasts to hypoxia. Arthritis Rheum 62(12): 3584-3594.
[9] Bustamante, M.F., R. Garcia-Carbonell, K.D. Whisenant, and M. Guma. 2017. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 19(1): 110.
[10] Elshabrawy, H.A., Z. Chen, M.V. Volin, S. Ravella, S. Virupannavar, and S. Shahrara. 2015. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis 18(4): 433-448.
[11] Nygaard, G., and G.S. Firestein. 2020. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol 16(6): 316-333.
[12] Elshabrawy, H.A., A.E. Essani, Z. Szekanecz, D.A. Fox, and S. Shahrara. 2017. TLRs, future potential therapeutic targets for RA. Autoimmun Rev 16(2): 103-113.
[13] Goh, F.G., and K.S. Midwood. 2012. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology (Oxford) 51(1): 7-23.
[14] Luo, L., R.M. Lucas, L. Liu, and J.L. Stow. 2019. Signalling, sorting and scaffolding adaptors for Toll-like receptors. J Cell Sci 133(5): jcs239194.
[15] Mcgarry, T., D.J. Veale, W. Gao, C. Orr, U. Fearon, and M. Connolly. 2015. Toll-like receptor 2 (TLR2) induces migration and invasive mechanisms in rheumatoid arthritis. Arthritis Res Ther 17(1): 153.
[16] Varoga, D., F. Paulsen, R. Mentlein, J. Fay, B. Kurz, R. Schütz, C. Wruck, M.B. Goldring, and T. Pufe. 2006. TLR-2-mediated induction of vascular endothelial growth factor (VEGF) in cartilage in septic joint disease. J Pathol 210(3): 315-324.
[17] Patra, M.C., and S. Choi. 2016. Recent progress in the development of Toll-like receptor (TLR) antagonists. Expert Opin Ther Pat 26(6): 719-730.
[18] Sujitha, S., and M. Rasool. 2017. MicroRNAs and bioactive compounds on TLR/MAPK signaling in rheumatoid arthritis. Clin Chim Acta 473: 106-115.
[19] Dulic, S., Z. Vasarhelyi, F. Sava, L. Berta, B. Szalay, G. Toldi, L. Kovacs, and A. Balog. 2017. T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy. Mediators Inflamm 2017: 6894374.
[20] Noack, M., and P. Miossec. 2017. Selected cytokine pathways in rheumatoid arthritis. Semin Immunopathol 39(4): 365-383.
[21] Gol-Ara, M., F. Jadidi-Niaragh, R. Sadria, G. Azizi, and A. Mirshafiey. 2012. The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis. Arthritis 2012: 805875.
[22] Chen, J.Q., P. Szodoray, and M. Zeher. 2016. Toll-Like Receptor Pathways in Autoimmune Diseases. Clin Rev Allergy Immunol 50(1): 1-17.
[23] Lawrence, T. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1(6): a001651.
[24] Mitchell, S., J. Vargas, and A. Hoffmann. 2016. Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med 8(3): 227-241.
[25] Li, L., X.J. Zhang, Y. Lan, L. Xu, X.Z. Zhang, and H.H. Wang. 2010. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule. Chin J Integr Med 16(1): 23-27.
[26] Wang, J., and G. Chen. 2020. Dimethylacetamide-induced toxic hepatitis in spandex workers: clinical presentation and treatment outcomes. Qjm 113(5): 324-329.
[27] Zhang, Q.Z., Y.L. Liu, Y.R. Wang, L.N. Fu, J. Zhang, X.R. Wang, and B.M. Wang. 2017. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. Exp Ther Med 14(3): 2689-2694.
[28] Okiyama, W., N. Tanaka, T. Nakajima, E. Tanaka, K. Kiyosawa, F.J. Gonzalez, and T. Aoyama. 2009. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress. J Hepatol 50(6): 1236-1246.
[29] Feng, T.T., X.Y. Yang, S.S. Hao, F.F. Sun, Y. Huang, Q.S. Lin, and W. Pan. 2020. TLR-2-mediated metabolic reprogramming participates in polyene phosphatidylcholine-mediated inhibition of M1 macrophage polarization. Immunol Res 68(1): 28-38.
[30] Ben-Ami Shor, D., T. Bashi, J. Lachnish, M. Fridkin, G. Bizzaro, I. Barshak, M. Blank, and Y. Shoenfeld. 2015. Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease. J Autoimmun 56: 111-117.
[31] Bashi, T., M. Blank, D. Ben-Ami Shor, M. Fridkin, M. Versini, O. Gendelman, A. Volkov, I. Barshak, and Y. Shoenfeld. 2015. Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine. J Autoimmun 59: 1-7.
[32] Novikova, N.S., A.S. Diatlova, K.Z. Derevtsova, E.A. Korneva, T.V. Viktorovna, Y. Ostrinki, L. Abraham, S. Quinn, Y. Segal, L.P. Churilov, M. Blank, Y. Shoenfeld, R. Aharoni, and H. Amital. 2019. Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis. J Neuroimmunol 337: 577070.
[33] Pan, W., W.T. Hao, H.W. Xu, S.P. Qin, X.Y. Li, X.M. Liu, F.F. Sun, H. Li, R.X. Tang, and K.Y. Zheng. 2017. Polyene Phosphatidylcholine inhibited the inflammatory response in LPS-stimulated macrophages and ameliorated the adjuvant-induced rat arthritis. Am J Transl Res 9(9): 4206-4216.
[34] Miyoshi, M., and S. Liu. 2018. Collagen-Induced Arthritis Models. Methods Mol Biol 1868: 3-7.
[35] Yoshino, S., and M. Ohsawa. 2000. The role of lipopolysaccharide injected systemically in the reactivation of collagen-induced arthritis in mice. Br J Pharmacol 129(7): 1309-1314.
[36] Erridge, C., S. Kennedy, C.M. Spickett, and D.J. Webb. 2008. Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. J Biol Chem 283(36): 24748-24759.
[37] Wang, J., Y. Gao, F. Lin, K. Han, and X. Wang. 2020. Omentin-1 attenuates lipopolysaccharide (LPS)-induced U937 macrophages activation by inhibiting the TLR4/MyD88/NF-κB signaling. Arch Biochem Biophys 679: 108187.
[38] Kuriakose, S., C. Onyilagha, R. Singh, F. Olayinka-Adefemi, P. Jia, and J.E. Uzonna. 2019. TLR-2 and MyD88-Dependent Activation of MAPK and STAT Proteins Regulates Proinflammatory Cytokine Response and Immunity to Experimental Trypanosoma congolense Infection. Front Immunol 10: 2673.
[39] Chen, D.Y., F. Yu, L.W. Tuan, and C.H. Tang. 2019. Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan. Front Pharmacol 10: 1214.
[40] Ben-Ami Shor, D., J. Lachnish, T. Bashi, S. Dahan, A. Shemer, Y. Segal, O. Shovman, G. Halpert, A. Volkov, I. Barshack, H. Amital, M. Blank, and Y. Shoenfeld. 2019. Immunomodulation of Murine Chronic DSS-Induced Colitis by Tuftsin-Phosphorylcholine. J Clin Med 9(1): 65.
[41] Bashi, T., O. Shovman, M. Fridkin, A. Volkov, I. Barshack, M. Blank, and Y. Shoenfeld. 2016. Novel therapeutic compound tuftsin-phosphorylcholine attenuates collagen-induced arthritis. Clin Exp Immunol 184(1): 19-28.
[42] Mendel, I., E. Feige, N. Yacov, Y. Salem, I. Levi, O. Propheta-Meiran, A. Shoham, E. Ishai, J. George, D. Harats, and E. Breitbart. 2014. VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin Exp Immunol 175(1): 126-137.
[43] Eros, G., S. Ibrahim, N. Siebert, M. Boros, and B. Vollmar. 2009. Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritis. Arthritis Res Ther 11(2): R43.
[44] Abdelwahab, A., S. Palosaari, S.A. Abdelwahab, R.A. Rifaai, N.F. El-Tahawy, E.A. Saber, T. Nousiainen, M. Valkealahti, J. Huhtakangas, T.J. Karttunen, and P. Lehenkari. 2021. Differential synovial tissue expression of TLRs in seropositive and seronegative rheumatoid arthritis: A preliminary report. Autoimmunity 54(1): 23-34.
[45] Arleevskaya, M.I., R.V. Larionova, W.H. Brooks, E. Bettacchioli, and Y. Renaudineau. 2020. Toll-Like Receptors, Infections, and Rheumatoid Arthritis. Clin Rev Allergy Immunol 58(2): 172-181.
[46] Balka, K.R., and D. De Nardo. 2019. Understanding early TLR signaling through the Myddosome. J Leukoc Biol 105(2): 339-351.
[47] Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663.